Estimaciones de analistas de Wall Street para Lexicon Pharmaceuticals, Inc. (LXRX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 7 |
| Venta | 2 |
| Venta fuerte | 0 |
| Analistas totales | 14 |
| Calificación media (1-5) | 0.21 |
Ratios de valoración
| Precio / Valor contable | 5.07 |
| EV / EBITDA | -18.63 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $83.3M | $90.3M | $63.2M | $322.1M | $24.0M | $298000 | $139000 | $1.2M | $31.1M | $49.8M |
| Coste de Ventas | $164.0M | $1.9M | $2.5M | $3.2M | $1.9M | $55.0M | $52.5M | $59.0M | $616000 | $274000 |
| Beneficio Bruto | -$80.6M | $88.4M | $60.7M | $318.8M | $22.1M | -$54.7M | -$52.4M | -$57.8M | $30.5M | $49.5M |
| I+D | $178.2M | $156.8M | $100.2M | $91.9M | $153.6M | $55.0M | $52.8M | $58.9M | $84.5M | $61.1M |
| Generales y Administrativos | $43.0M | $66.2M | $63.8M | $56.8M | $47.2M | 0 | 0 | 0 | $131.9M | $37.3M |
| Gastos Operativos | $221.2M | $223.0M | $164.0M | $177.4M | $69.9M | $32.3M | $48.4M | $114.0M | $227.6M | $98.4M |
| Beneficio Operativo | -$137.2M | -$136.7M | -$103.3M | $141.4M | -$47.8M | -$87.1M | -$100.8M | -$171.8M | -$197.1M | -$48.9M |
| EBITDA | -$125.8M | -$125.3M | -$96.1M | $148.4M | -$41.1M | -$86.7M | -$100.0M | -$169.8M | -$184.3M | -$41.4M |
| Gastos por Intereses | $6.6M | $7.0M | $20.8M | $20.7M | $14.5M | $802000 | $2.8M | $13.1M | $15.6M | $8.3M |
| Beneficio Antes de Impuestos | -$141.4M | -$141.7M | -$120.5M | $124.1M | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| Impuestos | $4.5M | -$12.7M | 0 | -$6.0M | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$141.4M | -$129.1M | -$120.5M | $130.1M | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| BPA | $-1.36 | $-1.23 | $-1.14 | $1.23 | $-0.63 | $-0.61 | $-0.62 | $-0.80 | $-0.63 | $-0.14 |
| BPA Diluido | $-1.36 | $-1.23 | $-1.14 | $1.11 | $-0.63 | $-0.61 | $-0.62 | $-0.80 | $-0.63 | $-0.14 |
| Acciones en Circulación (Diluidas) | $103.9M | $105.2M | $105.8M | $116.7M | $110.8M | $145.7M | $165.7M | $221.1M | $320.0M | $363.1M |
Precio
| Precio | $2.02 |
| Capitalización | $897M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADCT · BCYC · CMPX · FDMT · FULC · GOSS · NMRA
Explorar sector: Healthcare · Biotechnology
Más secciones de LXRX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones